Address: Janssen-Cilag, Department of Johnson-Johnson S.E., Bulevar Mihajla Pupina 248, 11000 Belgrade, Serbia
Tel:
Web: http://www.janssen-emea.com/
The international company Janssen-Cilag was established in 1994 as a result of merger of two Johnson&Johnson divisions, viz. Cilag (short for Chemische Industrie-Labor AG) and Janssen Pharmaceutica.
Janssen-Cilag that accounts for the development of more than 80 original drugs has twice received the prestigious international Galenic Prize for pharma achievements (for Rispolept in 1996; for Velcade in 2006). The company’s main fields are psychiatry, neurology, and gastroenterology; besides, it specializes in pain and mycose therapies.
The company will develop sustainable, integrated health care solutions by working with patients, physicians and other stakeholders, based on partnerships of trust and transparency. It will continue to invest in our people to realize their personal growth and to build our leaders of the future.
Janssen makes a big difference in the health and well-being of people every day. The company is operational in all countries thoughout Europe employing more than 6,000 people.
We will focus our energy on five major therapeutic areas of unmet need:
– Neuroscience (schizophrenia, dementia, pain …),
– Infectious Diseases (HIV/AIDS, Hepatitis C, tuberculosis, …),
– Oncology (multiple myeloma, prostate cancer, …),
– Immunology (psoriasis, …),
– Metabolism (diabetes, …).
The managing director of Janssen Hungary, Andreas Woitossek, depicts the valuable role of real-world evidence in enabling the affiliate’s consistent double-digit growth over the last four years, while highlighting the…
Janssen-Cilag has been investing heavily in its Latin American operations in the past years. What is the relative importance of the Chilean operations for Janssen-Cilag in Latin America and what…
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
When we spoke to Javier Lombar of IMS Argentina, he explained that a lot of multinational companies use Argentina as a base for regional operations. How does Janssen-Cilag operate in…
In a market environment that, up until recently, has been severely difficult for producers of chemical pharmaceutical products to operate in, three enterprising Serbian companies – Pharmanova, INNventa and Esensa…
Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in…
Nebojsa Skuljec has held various positions in MSD Healthcare across the Balkans before his promotion to country lead for Serbia and Balkans emerging markets 14 months ago. In this interview…
Branislav Kotlarik, Ferring’s general manager for the Balkans – whose remit includes Hungary, Romania and Bulgaria as well as all of ex-Yugoslavia – gives his insights into managing such a…
Gordana Zdravkovic has overseen the progression of BIOTEC International, Serbia through thick and thin. With over 25 years’ experience in the life sciences industry, she has put together a fantastic…
By reorganizing their management structure, diversifying their offering and presenting an altogether cleaner image, AstraZeneca Serbia has made tremendous progress since its beginnings in the Balkans in the late 1990s.…
Dragan Odzaklijevic, CEO of acb, the exclusive correspondent of leading global insurance broker Aon in Serbia, discusses the Serbian insurance market, which of acb’s services are most in demand for…
Nenad Djordjevic, managing director of Esensa, introduces the Belgrade company’s 200-strong portfolio of medical devices, food supplements, cosmetics and general use items; how it is now exporting its ‘made in…
Ana Grujovic, executive director of the Swiss-Serbian Chamber of Commerce (SSCC) who has been overseeing Swiss-Serbian business relations since 2014, explains the successful progression of the Chamber since its establishment,…
Ana Popovic, general manager of Serbia’s generics association, Genezis, gives her thoughts on how the generics industry has progressed in the country, what room for improvement remains, and the impact…
Suzana Djordjevic, director of the Hemofarm Foundation in Serbia, explores the themes of collectivism, social care and how individual acts can have profound outcomes in today’s world. Having enjoyed a…
Ljubiša Mitof-Višurski, general manager for AbbVie Adria, discusses the main challenges, opportunities and synergies the Adria region has to offer. He underlines the key healthcare initiatives AbbVie engages with in…
See our Cookie Privacy Policy Here
